Literature DB >> 17202706

Jorunnamycins A-C, new stabilized renieramycin-type bistetrahydroisoquinolines isolated from the Thai nudibranch Jorunna funebris.

Kornvika Charupant1, Khanit Suwanborirux, Surattana Amnuoypol, Emi Saito, Akinori Kubo, Naoki Saito.   

Abstract

Jorunnamycins A-C (1a-c), three stabilized renieramycin-type bistetrahydroisoquinolines, were isolated from the mantles, the visceral organs, and the egg ribbons of the Thai nudibranch Jorunna funebris that was pretreated with potassium cyanide (KCN), along with five known compounds, renieramycins M (2m), N (2n), O (2o), and Q (2q) and mimosamycin (3). The structures of 1a-c were elucidated from spectroscopic data and by chemical conversion of renieramycin M (2m) into 1c via 1a. The chemical stability and the oxidative degradation generating simple isoquinoline alkaloids of a carbinolamine analog 1d, which was easily prepared by reacting 1c with silver nitrate in aqueous acetonitrile, are discussed. The results of cytotoxicity studies are also presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202706     DOI: 10.1248/cpb.55.81

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  9 in total

1.  Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata.

Authors:  Peter Sima; Vaclav Vetvicka
Journal:  World J Clin Oncol       Date:  2011-11-10

2.  Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.

Authors:  Eric R Welin; Aurapat Ngamnithiporn; Max Klatte; Guillaume Lapointe; Gerit M Pototschnig; Martina S J McDermott; Dylan Conklin; Christopher D Gilmore; Pamela M Tadross; Christopher K Haley; Kenji Negoro; Emil Glibstrup; Christian U Grünanger; Kevin M Allan; Scott C Virgil; Dennis J Slamon; Brian M Stoltz
Journal:  Science       Date:  2018-12-20       Impact factor: 47.728

Review 3.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

Review 4.  Bioactive Compounds from Marine Heterobranchs.

Authors:  Conxita Avila; Carlos Angulo-Preckler
Journal:  Mar Drugs       Date:  2020-12-21       Impact factor: 5.118

Review 5.  Marine Migrastatics: A Comprehensive 2022 Update.

Authors:  Marzia Vasarri; Emanuela Barletta; Donatella Degl'Innocenti
Journal:  Mar Drugs       Date:  2022-04-19       Impact factor: 6.085

Review 6.  Application of the Asymmetric Pictet-Spengler Reaction in the Total Synthesis of Natural Products and Relevant Biologically Active Compounds.

Authors:  Majid M Heravi; Vahideh Zadsirjan; Masumeh Malmir
Journal:  Molecules       Date:  2018-04-18       Impact factor: 4.411

7.  Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.

Authors:  Kornvika Charupant; Khanit Suwanborirux; Naomi Daikuhara; Masashi Yokoya; Rie Ushijima-Sugano; Takatoshi Kawai; Takashi Owa; Naoki Saito
Journal:  Mar Drugs       Date:  2009-10-19       Impact factor: 5.118

8.  Jorunnamycin A Suppresses Stem-Like Phenotypes and Sensitizes Cisplatin-Induced Apoptosis in Cancer Stem-Like Cell-Enriched Spheroids of Human Lung Cancer Cells.

Authors:  Somruethai Sumkhemthong; Supakarn Chamni; Gea U Ecoy; Pornchanok Taweecheep; Khanit Suwanborirux; Eakachai Prompetchara; Pithi Chanvorachote; Chatchai Chaotham
Journal:  Mar Drugs       Date:  2021-05-03       Impact factor: 5.118

9.  Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.

Authors:  Jortan O Tun; Lilibeth A Salvador-Reyes; Michael C Velarde; Naoki Saito; Khanit Suwanborirux; Gisela P Concepcion
Journal:  Mar Drugs       Date:  2019-09-16       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.